Point72 Hong Kong LTD Nurix Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $234 - $376	19 New	19 $0
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $8,738 - $16,435	-1,109 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $10,921 - $25,024	844 Added 318.49%	1,109 $16,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $7,003 - $9,142	265 New	265 $8,000
Q3 2021 Nov 15, 2021	SELL	$22.71 - $36.69 $2,634 - $4,256	-116 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$24.21 - $35.89 $6,391 - $9,474	-264 Reduced 69.47%	116 $3,000
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $10,252 - $19,064	380 New	380 $12,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.